GlassScriptPhysician profile
Ricardo Munoz
NPI 1306848585
$1,659.53
in general payments reported to CMS, 2019-2025
28 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $115 · 2021: $436 · 2022: $357 · 2023: $110 · 2024: $202 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $370.26 | 2020-2024 | |
| Mayne Pharma Commercial LLC | $152.02 | 2024-2025 | |
| Becton, Dickinson and Company | $127.68 | 2021-2025 | Arista |
| Evofem Biosciences, INC. | $127.61 | 2020-2025 | Phexxi, Solosec, Phexx |
| Organon LLC | $125.05 | 2022-2025 | Nexplanon |
| Caldera Medical, INC | $102.28 | 2021-2025 | |
| Coopersurgical, INC. | $59.00 | 2022-2024 | Paragard T 380a |
| Shield Therapeutics INC | $56.93 | 2023-2025 | Accrufer |
| Hologic Sales and Service, LLC | $56.14 | 2019-2021 | |
| Avion Pharmaceuticals | $51.82 | 2020-2022 | |
| Duchesnay USA Incorporated | $50.61 | 2019 | |
| Astellas Pharma US INC | $49.05 | 2024-2025 | Veozah |
| Lupin INC. | $43.57 | 2019-2021 | |
| Covidien LP | $36.96 | 2020 | |
| Agile Therapeutics, INC. | $33.28 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $28.93 | 2022 | |
| Axonics, INC. | $27.41 | 2024 | Axonics |
| Biogen, INC. | $20.86 | 2025 | Zurzuvae |
| Intuitive Surgical, INC. | $19.85 | 2019 | |
| Merck Sharp & Dohme LLC | $17.70 | 2021 | |
| Tactile Systems Technology INC | $16.53 | 2025 | Flexitouch Plus, Nimbl |
| Ferring Pharmaceuticals INC. | $16.08 | 2019 | |
| Meditrina | $14.91 | 2022 | |
| Pfizer INC. | $14.75 | 2022 | |
| Myovant Sciences INC. | $14.64 | 2021 | |
| Exeltis, USA INC. | $13.98 | 2025 | Slynd |
| Scynexis, INC. | $11.63 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.